ABSTRACT
INTRODUCTION
Lower urinary tract symptoms (LUTS) are a common problem in older men that increases steeply with age [1, 2] . Approximately 50% of Enhanced content for Advances in Therapy articles is available on the journal web site: www.advancesintherapy.com men 70-80 years of age report moderate-tosevere LUTS, with significant bother, and impact on quality of life [3] [4] [5] . They can be subcategorized into storage symptoms (frequency, urgency, nocturia, urinary incontinence), voiding symptoms (slow stream, splitting, intermittency, hesitancy, straining, dribble), and postmicturition symptoms (sensation of incomplete emptying, postmicturition dribble), and can be quantified with validated and internationally accepted questionnaires, the International Prostate Symptom Score (IPSS) being most widely used [6, 7] . Infravesical obstruction by benign prostatic enlargement (BPE) resulting from benign prostatic hyperplasia (BPH) has been assumed to be the main cause of the problem.
Indeed, 48-60% of men >60 years of age seen by general practitioners have a clinically enlarged prostate and approximately one third have both moderate-to-severe LUTS and an enlarged prostate [3, 8] . Larger prostate volume has been correlated with more severe LUTS and a higher risk of progression of symptoms and complications [9] . The etiology of LUTS is in fact more complex and multifactorial [6, 7, 10] . The patient consulting his doctor because of LUTS primarily seeks relief from his symptoms, but he also worries about further deterioration and complications requiring more invasive treatment such as surgery. This is not without foundation; LUTS assumed to be caused by BPH are progressive over time [9, 12] and the overall risk of acute urinary retention in population studies has been estimated at up to 23% for an average 60-year-old man if he survives another 20 years [13] .
In view of the high prevalence of bothersome LUTS the diagnostic approach to the problem has to be fairly simple and straightforward. In general, a thorough history (with quantification of symptoms and quality of life issues; IPSS), a voiding chart (the physician should rule out nocturia, polyuria, and polydipsia), physical examination (with digital rectal examination of the prostate), urinalysis, determination of serum prostate-specific antigen (PSA), ultrasonography of the bladder, prostate, upper urinary tract (with determination of postvoid residual urine), and uroflowmetry provide all information needed for therapeutic decisions, at least on a nonsurgical level [2] . In men >50 years of age with an IPSS >7, no evidence of excessive nocturia, an enlarged prostate, maximum urinary flow rates <12 mL/sec, and postvoid residual urine <150 mL, BPO resulting from prostatic enlargement is the most likely cause of the problem [14] . Serum PSA levels >1.5 ng/mL have also proven fairly reliable surrogate markers of BPE once cancer is excluded [15] . Prostate volume and serum PSA are the most reliable prognosticators for the risk of symptom progression and the occurrence of complications such as acute urinary retention or the need for surgery [16] .
Mild LUTS (IPSS ≤7) can usually be managed with simple lifestyle advice, such as avoiding excessive fluid intake and moderating caffeine and alcohol consumption [17] . With an IPSS >7, consistent with moderate-to-severe LUTS, and clinical findings as described above, medical therapy becomes the first line of management [6, 18, 19] .
METHODS
The findings presented here are an interpretation of the present literature, and not the result of a systematic literature search by the author, which also reflects the situation of most guidelines on this topic [6, 18, 19] .
DISCUSSION

Single-Agent Therapy
Alpha-1 Adrenoceptor Antagonists (Alpha-1
Blockers)
Contraction of the smooth muscle of the prostate and bladder neck by endogenously released noradrenaline is primarily regulated by alpha-1A adrenoceptors, although alpha-1B and alpha-1D subtypes in the bladder and nervous system may also play a role [20, 21] . Blocking The therapeutic efficacy of all alpha-1 blockers currently licensed for the treatment of LUTS assumed to be caused by BPH appears fairly similar [23, 24] , but their adverse effect profiles differ significantly, apparently due to their variable alpha-1 receptor subselectivity.
Older agents, such as doxazosin and terazosin, also affect alpha-1B adrenoceptors in blood vessels and dosage has to be titrated according to individual tolerance. Alfuzosin, tamsulosin, and silodosin have less vasodilating effects and hence cause less asthenia, dizziness, and orthostatic hypotension. There is no significant impact on libido or erectile function, but tamsulosin and in particular silodosin may cause an absence of ejaculation, apparently due to a distinctly higher specificity to alpha-1A receptors [25] .
Alpha-1 blockers, in particular tamsulosin, have been shown to cause intraoperative floppy iris syndrome at cataract surgery; therefore, they should be stopped well ahead of the procedure, and the ophthalmologist informed [26] .
It is, at present, common consensus in major guidelines that alpha-1 blockers should be offered to men with moderate-to-severe LUTS based on level 1a evidence [6, 18, 19] 
5-alpha-Reductase Inhibitors
BPH causing prostatic enlargement is androgen driven and at the cellular level this is mainly mediated by dihydrotestosterone (DHT).
Testosterone is converted to DHT by the nuclearbound steroid enzyme 5-alpha reductase.
If blocked, this mechanism is interrupted without impairing androgen activity outside of the prostate. 5-alpha reductase exists in two isoenzymes; type 2 is predominantly expressed in benign prostatic tissues and type 1 mainly in skin and liver, but also in prostate cancer cells [27] [28] [29] . PSA is monitored at regular intervals thereafter (in general every 6 months) and any confirmed increase from the lowest value measured thereafter, a "nadir," should be considered a warning flag of possible cancer and trigger the appropriate diagnostic measures [48] .
Antimuscarinics
Although older men with BPE report a higher prevalence of voiding than storage symptoms, the latter are more bothersome and tend to affect quality of life more profoundly [5] . Patients with small prostates and/or PSA levels <1.3 ng/mL seem to benefit more [52] , but there is general agreement that antimuscarinic monotherapy should be approached with caution in men with LUTS and BPE; close urologic surveillance is mandatory [6, 18, 19] .
Phosphodiesterase-5 Inhibitors
Prospective, placebo-controlled, randomized trials have shown that phosphodiesterase-5 inhibitors (PDE-5 Is) improve LUTS in men assumed to be caused by BPO [53, 54] . Biologically active PDE-5 is expressed in the musculature of the bladder neck, prostatic urethra, and prostate [55] , and its inactivation had been postulated to relieve outflow obstruction until this was disproven by Dmochowski et al [56] . This has not really been confirmed urodynamically, and more complex mechanisms affecting an increased bladder/prostate afferent activity may also play a role [56] . A recent systematic analysis of seven prospective studies comparing PDE-5 Is monotherapy versus placebo in >2,000 men demonstrated consistent improvement of LUTS and erectile function, but no change in flow rates [57] . Symptom improvement was similar across all PDE-5 Is and dosages studied.
Younger men with lower body mass index and more severe LUTS seemed to benefit most. Adverse events were consistent with those documented in the treatment of erectile dysfunction and mainly consisted of flushing, gastroesophageal reflux, dyspepsia, and headache [57] . All studies were limited by short duration, usually 12 weeks, and the lack of adequately powered direct comparison to approved agents, such as alpha-1 blockers [57, 58] . Although PDE-5 Is are already approved for the treatment of male LUTS in the US and Europe, recent guidelines still suggest that they be used cautiously [6, 18, 19] . 
Combination Therapy
Given the complex and multifactorial etiology of LUTS and clear limitations of all single-agent approaches combining drugs with different modes of action to achieve synergistic effects appears a logical development [58] .
Alpha-1 Blockers and 5-ARIs
Alpha-1 blockers provide rapid symptom improvement within weeks, but cannot prevent disease progression and acute urinary retention.
5-ARIs achieve the latter, but take months and an enlarged prostate, although the definition of "enlarged" varies from no precise definition [6] to prostate volumes >30-40 mL [18, 19] . Differing opinions on this issue only exist on the lower cut-off value of prostate volume above which this combination becomes the first-line therapy.
A posthoc subanalysis of MTOPS data suggested advantages over alpha-1 blocker monotherapy already at baseline prostate volumes >25 cc [40] .
In the CombAT trial, patients had to have a prostate volume >30 mL to be admitted to the study; combination therapy reduced symptom deterioration across all baseline subgroups, but this did not reach statistical significance at prostate volumes <40 mL [39] . With an inherent variation of prostate volume measurements by ultrasonography of about ± 15% a precise threshold is clinically probably overstated.
Therefore, the larger the prostate the higher the risk of disease progression and the more pronounced the benefits of combining an alpha-1
blocker with an ARI with long-term treatment.
Alpha-1 Blockers and Antimuscarinics
In the first major prospective randomized trial 
